TCT-775 Transapical Transcatheter Aortic Valve Implantation in Patients with Reduced Left Ventricular Ejection Fraction: Comparison of Balloon-expandable and Self-expanding Prostheses  by Schirmer, Johannes et al.
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comResults: Flow acceleration occurred in-stent but proximal to the cusps and again at the
level of the cusps in all pts. EOA and DVI calculated using P-S values was signiﬁ-
cantly lower than when using I-SPC values. See table.Pre-stent (P-
S)
In-stent pre-cusp (I-
SPC) p
Effective oriﬁce area (EOA),
cm2
1.81  0.36 2.30  0.42 <0.0001
Doppler velocity index (DVI) 0.44  0.10 0.55  0.11 <0.0001
Peak velocity, m/sec 0.80  0.16 1.05  0.22 <0.0001
Peak gradient, mmHg 2.7  1.2 4.6  2.0 <0.0001
Mean gradient, mmHg 1.5  0.8 2.4  1.1 <0.0001
VTI , cm 15.2  3.9 19.2  4.2 <0.0001
Stroke volume, ml 63.9  18.5 81.1  22.9 <0.0001Conclusions: There is hemodynamically signiﬁcant ﬂow acceleration within the
CoreValve stent proximal to the cusps. Failure to recognize the importance of pre-
stent PW Doppler sample volume placement may result in inaccurate and inconsistent
assessment of Corevalve EOA and DVI.
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Background: A postprocedural increase of the serum troponin I concentration (TnI)
reﬂects myocardial injury and occurs frequently during transcatheter aortic valve
implantation (TAVI). Periprocedural coronary microembolization is a potential cause
of such injury. We therefore evaluated each step of the transfemoral TAVI procedureB226 JACC Vol 64/11/Suppl B j Sepfor coronary embolization using intracoronary Doppler (ICD) in the left anterior
descending (LAD) artery.
Methods: 15 high-risk patients with severe, symptomatic aortic valve stenosis who
underwent transfemoral TAVI using the balloon-expandable Edwards bioprosthesis
were included. ICD examinations were recorded and evaluated off-line for high-in-
tensity transient signals (HITS). Perioperative concentrations of TnI were serially
measured within the ﬁrst 72 h after TAVI, and a cardiac MRI with late gadolinium-
enhancement (LGE) was performed within 7 days.
Results: HITS were detected in all patients, mostly during the initial crossing of the
native valve and positioning of the prosthesis with subsequent implantation. TnI
peaked at 24 h after TAVI (3.17 ng/ml), and LGE was observed in only one single
case. There was no correlation between amount of HITS and TnI area under the curve
in the ﬁrst 72 h after TAVI.Conclusions: Procedural HITS were detected by ICD in all patients undergoing
transfemoral TAVI. The highest amount of HITS was observed during initial valve
passage and positioning of the prosthesis with subsequent implantation. However, no
association was found between the number of HITS and myocardial injury, as re-
ﬂected by increased serum TnI concentrations or LGE on cardiac MRI.
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Background: The adverse impact of left ventricular dysfunction on survival after
transcatheter aortic valve implantation (TAVI) has been documented. We report our
experience with transapical TAVI in patients with reduced left ventricular function
(LVEF) comparing ﬁrst (balloon-expandable) and second (self-expanding) generation
TAVI devices.
Methods: From 3/2008 through 12/2012, a total of 75 patients presenting with pre-
procedural LVEF45% underwent transapical TAVI, implanting either balloon-
expandable prostheses (Edwards Sapien/Sapien XT) in 48 patients (BE; mean age
78.27.9 years, 71% male) or self-expanding prostheses (JenaValve, n¼12; Symetis
Accurate, n¼9; Medtronic Engager, n¼6) in 27 patients (SE; mean age 79.56.7
years, 63% male), respectively. Calculated logistic EuroSCORE II and STS mortality
scores were 12.67.4% (BE) vs. 10.85.4% (SE) (p¼ns) and 9.26.6% (BE) vs.
9.27.3% (SE) (p¼ns). Clinical and functional data were analysed according to the
Valve Academic Research Consortium (VARC) endpoints.
Results: Cumulative survival rates at 30 days and at one year were 87.5% (BE) vs.
96.3% (SE) (p¼ns) and 52.0% (BE) versus 60.5% (SE) (p¼ns), respectively. VARC
device success and VARC combined 30-day safety endpoints were achieved in 87.5%
(BE) vs. 85.2% (SE) (p¼ns) and 31.3% (BE) vs. 18.5% (SE) (p¼ns), respectively.
Post-procedural aortic regurgitation >grade 1 did not differ between groups (8.4%
(BE) vs. 11.1% (SE), p¼ns). However, aortic regurgitation grade 1 was observed in
50.0% (BE) vs. 37.0% (SE) (p¼0.016). New onset of pacemaker indication was
present in 10.4% (BE) vs. 7.4% (SE) (p¼ns). Mean ICU stay was 2.52.6 days (BE)
vs. 2.01.8 days (SE) (p¼ns), whilst post-procedural hospital stay was 10.03.8 days
(BE) vs. 10.66.6 days (SE) (p¼ns).
Conclusions: Comparable survival rates and VARC endpoints were achieved in pa-
tients with reduced LVEF undergoing transapical TAVI either with balloon-expand-
able or with self-expanding prostheses. Further studies are required to evaluate the
impact of a lower incidence of mild aortic regurgitation following implantation of self-
expanding valve types when compared to balloon-expandable prosthetic valves.tember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
